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Higher low-density lipoprotein cholesterol (LDL-C) con-centration is associated with a higher risk of coronary 
heart disease (CHD), and the relationship is considered causal 
because randomized trials using LDL-lowering interventions 
such as statins have shown to reduce CHD risk in proportion to 
the LDL-C reduction.1,2 Interventions to elevate high-density 
lipoprotein cholesterol (HDL-C) or reduce triglycerides (TGs) 
might also confer incremental protection against CHD, but thus 
far randomized trials of drugs directed at these 2 lipid fractions 
have been unable to confirm or refute such effects.3–7
Clinical Perspective on p 72
Conclusive demonstration of the benefit and safety of new 
lipid-modifying interventions requires evaluation in large, 
Background—Carotid intima–media thickness (CIMT), a subclinical measure of atherosclerosis, is associated with risk of 
coronary heart disease events. Statins reduce progression of CIMT and coronary heart disease risk in proportion to the 
reduction in low-density lipoprotein cholesterol. However, interventions targeting triglycerides (TGs) or high-density 
lipoprotein cholesterol (HDL-C) have produced inconsistent effects on CIMT and coronary heart disease risk, making 
it uncertain whether such agents are ineffective for coronary heart disease prevention or whether CIMT is an inadequate 
marker of HDL-C or TG-mediated effects. We aimed to determine the causal association among the 3 major blood lipid 
fractions and common CIMT using mendelian randomization analysis.
Methods and Results—Genetic scores specific for low-density lipoprotein cholesterol, HDL-C, and TGs were derived 
based on single nucleotide polymorphisms from a gene-centric array in ≈5000 individuals (Cardiochip scores) and from 
a genome-wide association meta-analysis in >100 000 individuals (Global Lipids Genetic Consortium scores). These 
were used as instruments in a mendelian randomization analysis in 2 prospective cohort studies. A genetically predicted 
1 mmol/L higher low-density lipoprotein cholesterol concentration was associated with a higher common CIMT by 
0.03 mm (95% confidence interval, 0.01–0.04) and 0.04 mm (95% confidence interval, 0.02–0.06) based on the Cardiochip 
and Global Lipids Genetic Consortium scores, respectively. HDL-C and TGs were not causally associated with CIMT.
Conclusions—Our findings confirm a causal relationship between low-density lipoprotein cholesterol and CIMT but not 
with HDL-C and TGs. At present, the suitability of CIMT as a surrogate marker in trials of cardiovascular therapies 
targeting HDL-C and TGs is questionable and requires further study. (Circ Cardiovasc Genet. 2013;6:63-72.)
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expensive randomized trials with hard clinical end points in 
people already receiving effective drugs for CHD prevention. 
Approaches that help validate treatment targets ahead of such 
trials may help reduce the risk of late-stage failures in drug 
development. One approach has been to use a noninvasive 
measure of atherosclerosis, carotid intima–media thickness 
(CIMT), as a surrogate end point. CIMT is considered to be 
a subclinical measure of atherosclerosis, which is strongly 
associated with risk of CHD.8,9 LDL-C–lowering statin drugs 
that are effective in reducing CHD also reduced progression 
of CIMT in proportion to the degree of LDL-C lowering.10–12 
However, interventions developed so far that reduce TGs or 
raise HDL-C have shown inconsistent effects on CIMT,13–15 
making it uncertain whether the specific agents are ineffective 
for CHD prevention, whether these 2 lipid fractions, in gen-
eral, are not causally related to CHD and, therefore, invalid 
targets, or whether CIMT is an inadequate marker of HDL-C 
or TG-mediated effects on CHD risk.
Mendelian randomization (MR) provides a means of evalu-
ating and quantifying the extent to which associations between 
a putative risk factor (eg, HDL-C or TGs) and an outcome, 
such as CHD or CIMT, are causal.16 MR uses genetic vari-
ants as proxies for the risk factor of interest to overcome some 
common limitations of nongenetic observational studies. The 
random allocation of parental alleles to offspring at meiosis 
results in population distributions of genetic variants that are 
largely independent of environmental factors that typically 
confound epidemiological associations between putative risk 
factors and disease, while the unidirectional flow of biologi-
cal information from gene to risk factor and then to disease 
outcome avoids reverse causation.17
Using large-scale single-nucleotide polymorphism (SNP) 
arrays, many SNPs influencing LDL-C, HDL-C, and TGs have 
recently been identified,18,19 and these provide potential instru-
ments for MR analyses. Independently inherited SNPs contribut-
ing to the levels of these lipids act approximately additively, such 
that each individual in a population can be assigned a genetic 
score based on the number of trait-raising alleles carried. Genetic 
scores derived from a combination of variants should provide 
stronger and more specific instruments for lipid traits compared 
with a single SNP and increase the power to conduct MR analysis.
In this study, we generated genetic scores for LDL-C, HDL-C, 
and TGs based on SNPs present on the gene-centric Illumina 
Cardiochip20 that were found to be associated with each of the 3 
lipid fractions in the Whitehall II study (WHII).18 We used these 
genetic scores to estimate the causal association among the 3 major 
blood lipid fractions and common CIMT in ≈3000 participants from 
the WHII21 and ≈3400 individuals from the IMT Progression as 
Predictors of Vascular Events in a High Risk European Population 
(IMPROVE) study22 using an instrumental variable analysis. We 
compared the causal estimates with those derived using genetic 
scores based on the Global Lipids Genetic Consortium (GLGC) 
lipid-associated SNPs, which were independently identified by a 
meta-analysis in more than 100 000 individuals.19
Methods
Study Participants
WHII recruited 10 308 participants (70% men) between 1985 and 
1989 from 20 London-based Civil Service departments.21 The study 
was approved by the University College London (UCL) Research 
Ethics Committee, and participants gave informed consent to each 
aspect of the study. Clinical measurements were taken at 5-year inter-
vals. Clinical data were available from 4 phases (phase 1, 1985–1988; 
phase 3, 1991–1993; phase 5, 1997–1999; and phase 7, 2003–2004). 
Phase 3 (1991–1993) provided the first comprehensive phenotyping 
and is considered the baseline phase.
The IMPROVE study22 recruited 3711 individuals (48% men) 
between March 2004 and April 2005 from 7 centers in 5 European 
countries with a median age of 64.4 years. Eligibility criteria included 
age between 55 and 79 years, presence of at least 3 vascular risk fac-
tors, absence of symptoms of cardiovascular diseases, and any condi-
tions that might limit longevity or visualization of the carotid intima. 
The study was designed in accordance with the rules of Good Clinical 
Practice and with the ethical principles established in the Declaration 
of Helsinki. Informed consent was obtained from all participants. 
Baseline measures were available for this analysis.
Lipid and CIMT Measurements
In WHII, lipid measurements from phase 3 were used in this analysis 
because few participants were on lipid-modifying medication com-
pared with follow-up phases, whereas ultrasound vascular measure-
ments were only available at phase 7 (2003–2004). Measurement of 
serum lipids and common CIMT in WHII and IMPROVE is described 
in detail in the online-only Data Supplement Methods section.
Genotyping and Quality Control
For WHII participants, DNA was extracted from whole blood sam-
ples as previously described.18 Five thousand five hundred ninety-two 
samples were genotyped using the Illumina Human Cardiochip,20 and 
3413 were later genotyped using the Illumina Metabochip.23 After 
quality control (filtering for duplicates, cryptic relatedness, ambigu-
ous sex, self-reported nonwhites, outliers based on the genome-wide 
identity-by-state analysis implemented in PLINK, sample call rate 
<80%, and SNP call rate <98%), 5059 Cardiochip genotyped samples 
and 3126 Metabochip genotyped samples individuals were available 
for the analysis.
In the IMPROVE study, DNA was extracted as described by 
Baldassarre et al.22 In total, 3695 samples were genotyped using the 
Illumina Metabochip. After quality control (using call rate <95% and 
removing individuals for relatedness [confirmed or cryptic], reported 
non-European descent, outliers identified by multidimensional scal-
ing, estimated inbreeding [excessive homozygosity], and mismatch 
between recorded and genotype-determined sex), 3430 individuals 
remained for this analysis.
Derivation of Lipid Genetic Scores
Two lipid genetic scores were derived: 1 from a discovery-based anal-
ysis using the Illumina Human Cardiochip in WHII,18 and 1 based on 
lipid-associated variants reported by the GLGC.19
Cardiochip Score
SNPs previously found to be associated with baseline LDL-C, 
HDL-C, or TGs in WHII18 were included in a stepwise variable selec-
tion scheme with the Bayesian Information Criterion,24 implemented 
separately for each chromosome, to select the best genetic predictors 
for each lipid trait.18 For each lipid fraction, the risk allele counts 
(LDL-C and TG-raising alleles and HDL-C–reducing alleles) for the 
selected SNPs were weighted using the risk-allele β-coefficient ob-
tained from a ridge regression25 in WHII, using the Lawless and Wang 
estimate of the ridge constant.26 The ridge regression is a variant of 
ordinary multiple linear regression that shrinks the β-coefficients 
of redundant SNPs, thereby circumventing issues that may arise if 
highly correlated SNPs are retained by the variable selection model. 
In both the variable selection and ridge regression, sex and age were 
added in the baseline model. The final genetic score for each partici-
pant was the sum of the weighted risk allele count. Apolipoprotein E 
(APOE) is a major determinant of LDL-C levels, and the effect of the 
APOE haplotype was included in the LDL score calculation. Of the 
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2 SNPs that determine the major APOE isoforms (ApoE2, ApoE3, 
and ApoE4), only 1 (rs7412) is represented on the genome-wide and 
gene-centric platforms used in WHII and GLGC. In both studies, the 
2 SNPs (rs7412 and rs429358) had been separately genotyped, and 
haplotypes determined.22,27 We used the previously reported effect 
of the APOE haplotypes on LDL-C, from a meta-analysis in 61 463 
healthy participants, to generate a weighted APOE score. Based on 
the latter study, using ε3/ε3 individuals as reference,28 the APOE 
haplotype was scored as follows: ε2ε2=−0.9, ε2ε3=−0.4, ε2ε4=−0.2, 
ε3/ε3=0, ε3ε4=0.1, and ε4ε4=0.2. The SNPs used in the Cardiochip 
scores are shown in online-only Data Supplement Tables I–III. The 
same weights were used to calculate lipid genetic scores for individu-
als in the IMPROVE dataset.
GLGC Score
A threshold of P<5×10−8 was used by the GLGC to denote associa-
tion between SNPs and lipid traits.19 For the purpose of the genetic 
score calculation, only the lead SNP from each locus was selected, 
and if a SNP was associated with >1 lipid fraction, it was only used 
in the genetic score calculation for the trait with which it had the most 
significant association P value. Risk allele counts were calculated in 
WHII and IMPROVE and weighted using the reported univariate β-
coefficients. Because the discovery of these SNPs was performed in an 
independent dataset and only a single SNP was  selected at each locus, 
the issues of inflated instrument strength  because of discovery bias and 
linkage disequilibrium were minimized. The SNPs used in the GLGC 
scores are shown in online-only Data Supplement Tables I–III.
For both sets of scores, SNPs not present in the data (because 
they were not represented on the genotyping platform or failed 
quality control) were excluded from the genetic score calculations. 
Individuals with missing genotypes were also excluded from the 
analysis.
Strength and Association of Lipid Levels  
With Lipid Genetic Scores
We evaluated the association of lipid levels with their respective genetic 
scores using linear regression, with no adjustment for covariates. The 
proportion of variance explained (R2) and the F-statistic were reported 
as measures of the strength of each genetic score as an instrument.29 To 
show the benefit of using a combined genetic score as an instrument 
over a single SNP, we compared the R2 of the GLGC scores (because 
these are not affected by discovery bias) with the most strongly as-
sociated SNPs for each trait, namely, rs651821 (proxy for the APOA5 
SNP rs662799, previously reported to be associated with TG levels and 
CHD),30 rs17231506 (proxy for the CETP Taq1B polymorphism asso-
ciated with HDL-C), and the APOE haplotypes that create the ApoE2/
E3/E4 isoforms.
Direct Associations of Blood Lipid Fractions  
With CIMT
Association of CIMT with lipid levels was determined using linear 
regression, with and without adjustment for sex, age, smoking, diabe-
tes mellitus status, and statin use.
Instrumental Variable Analysis
To evaluate the causal association of each lipid fraction with CIMT, 
we performed an instrumental variable (IV) analysis using the 2-stage 
least squares method,31 whereby each genetic score was used as an 
instrumental variable for the unconfounded and unbiased effect of the 
respective lipid fraction on CIMT. No adjustment was made for co-
variates. A meta-analysis of the effect estimates was also performed 
using a fixed-effect model. We repeated the 2-stage least squares 
method analysis using lipid levels that were corrected for statin use. 
For statin users, the recorded lipid values were multiplied by a con-
stant: LDL-C by 1.352, HDL-C by 0.949, and TG by 1.210. The 
multiplicative correction factors were based on analysis of repeat-
edly measured lipid levels, including levels measured before and after 
lipid-lowering treatment, in WHII. This methodology has been used 
in the most recent large-scale lipid meta-analysis.32
Results
Study Characteristics
Population characteristics and sample sizes with both geno-
type and phenotype data are shown in Table 1. The mean age 
of IMPROVE participants in this analysis was 64.2 years 
(SD=5.4), similar to the mean age of WHII participants at 
the follow-up phase when CIMT measurements were taken 
(60.9 years [SD=6.0]). Mean CIMT in IMPROVE and WHII 
was 1.17 mm (±0.33) and 0.79 mm (±0.15), respectively. 
The lower mean LDL-C level in IMPROVE (3.55 mmol/L; 
SD=1.00) compared with WHII (4.37 mmol/L; SD=1.01) may 
partly be explained by the larger proportion of participants on 
statin medication (40% versus 0.9%, respectively).
Cardiochip Lipid Genetic Scores
Seventeen SNPs (including the 2 APOE SNPs genotyped 
separately) were used for the LDL genetic score, and 12 and 
13 SNPs, respectively, for the HDL and TG genetic scores 
(online-only Data Supplement Tables I–III). After applying 
quality control filters, all SNPs were available in the WHII 
dataset. In the IMPROVE dataset, 13 LDL (including 2 
APOE SNPs), 11 HDL, and 9 TG SNPs were available for 
the score calculation.
GLGC Lipid Genetic Scores
Of the lead SNPs reported by the GLGC meta-analysis, 12 
(including 2 APOE SNPs) were used for the GLGC LDL 
score, and 29 and 16 SNPs, respectively, were used for the 
HDL and TG genetic scores (online-only Data Supplement 
Tables I–III). In WHII, all LDL SNPs, 28 of 29 HDL SNPs, 
and all TG SNPs were present. In IMPROVE, 10 (including 
2 APOE SNPs) of 12 LDL SNPs, 28 of 29 HDL SNPs, and 
all TG SNPs were present in the genotype data after quality 
control filters were applied.
Table 1. Cohort Characteristics
Whitehall II IMPROVE
No. 5059 3430
Men % 74 48
Age
 Baseline 49.1 (5.9) 64.2 (5.4)
 Follow-up 60.9 (6.0) ...
Mean CIMT (SD), cm 0.79 (0.15) 1.17 (0.33)
Baseline mean LDL-C (SD), mmol/L 4.37 (1.01) 3.55 (1.00)
Baseline mean HDL-C (SD), mmol/L 1.43 (0.41) 1.26 (0.36)
Baseline mean triglyceride (SD), mmol/L 1.44 (1.11) 1.59 (1.24)
Baseline % on statins 0.87 40.3
Number of participants with
 CIMT measurement 3617 3430
 Cardiochip data 5059 0
 Cardiochip data and CIMT 3256 0
 Metabochip data 3126 3430
 Metabochip data and CIMT 2138 3430
CIMT indicates carotid intima–media thickness; HDL-C, high-density lipoprotein 
cholesterol; IMPROVE, IMT Progression as Predictors of Vascular Events in a High 
Risk European Population; and LDL-C, low-density lipoprotein cholesterol.
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Association of Lipid Levels With Lipid  
Genetic Scores
A 1 SD higher Cardiochip LDL genetic score was associ-
ated with 0.37 (95% confidence interval [CI], 0.34–0.39) and 
0.16 mmol/L (95% CI, 0.13–0.20) higher LDL-C in WHII 
and IMPROVE, respectively. A 1 SD higher HDL genetic 
score was associated with 0.11 (95% CI, 0.10–0.12) and 
0.08 mmol/L (95% CI, 0.07–0.09) lower HDL-C in WHII 
and IMPROVE, respectively. A 1 SD higher TGs genetic 
score was associated with 0.25 (95% CI, 0.22–0.28) and 
0.25 mmol/L (95% CI, 0.21–0.29) higher TGs in WHII and 
IMPROVE, respectively (Figure 1A). Differences in lipid 
 levels associated with the GLGC genetic scores were in the 
same direction but were slightly lower in magnitude in both 
studies (Figure 1B).
Lipid Genetic Scores as Instruments for  
MR Analysis
The Cardiochip genetic scores explained 13% and 3% of 
the total variance in LDL-C, 7% and 5% of the variance in 
HDL-C, and 5% and 4% of the variance in TGs in WHII and 
IMPROVE, respectively. The GLGC genetic scores explained 
11% and 2% of the total variance in LDL-C, 4% and 5% of 
the variation in HDL-C, and 2% and 2% of the variation in 
TGs levels in WHII and IMPROVE, respectively. All scores 
had large F-statistics (Table 2). The WHII R2 and F-statistics 
for the Cardiochip scores are likely to be inflated because of 
discovery bias, and the higher sample size in WHII for the 
Cardiochip scores will also contribute to a higher F-statistic. 
The considerably lower R2 values for the LDL genetic score 
in IMPROVE may reflect the large number of individuals on 
Figure 1. Association of lipid levels with 
lipid genetic scores. β-Coefficients repre-
sent mmol/L change in lipid levels per 1 
SD change in (A) Cardiochip lipid genetic 
scores and (B) Global Lipids Genetic Con-
sortium lipid genetic scores. CI indicates 
confidence interval; HDL-C, high-density 
lipoprotein cholesterol; IMPROVE, IMT 
Progression as Predictors of Vascular 
Events in a High Risk European Population 
Study22; LDL-C, low-density lipoprotein 
cholesterol; TG, triglyceride; and WHII, 
Whitehall II study.
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statins. In all cases, the genetic scores were much stronger 
instruments than individual SNPs. Comparison of the GLGC 
genetic scores with single SNPs in WHII is shown in online-
only Data Supplement Figure I, which also shows that the 
genetic scores have improved specificity as instruments over 
single SNPs with respect to the 3 lipid fractions.
Direct Association of Blood Lipid Fractions  
With CIMT
After adjustment for age, sex, smoking, diabetes mellitus 
status, and statin use, only LDL-C and HDL-C were associ-
ated with CIMT (Table 3). A 1 mmol/L higher LDL-C was 
associated with 0.01 mm (95% CI, 0.006–0.02) and 0.02 mm 
(95% CI, 0.005–0.03) higher CIMT in WHII and IMPROVE, 
respectively. A 1 mmol/L higher HDL-C was associated with 
0.02 mm (95% CI, 0.01–0.04) and 0.05 mm (95% CI, 0.02–
0.08) lower CIMT in WHII and IMPROVE, respectively.
Instrumental Variable Analysis
Based on the meta-analysis of the estimates derived from the 
instrumental variable analysis, a 1 mmol/L higher LDL-C was 
associated with 0.03 mm (95% CI, 0.01–0.04; P=0.0002) and 
0.04 mm (95% CI, 0.02–0.06; P<0.0001) higher CIMT, when 
using the Cardiochip and GLGC LDL genetic scores, respec-
tively, as instruments (Figure 2). HDL-C and TGs were not 
found to be associated with CIMT using instrumental variable 
analysis (Figure 2). There was no change in the overall IV esti-
mate when using lipid levels corrected for statin use (Figure 3).
Discussion
LDL-C, HDL-C, and TG genetic scores were used in a MR anal-
ysis to assess the causal relationship between each lipid fraction 
and CIMT. Although there was a positive association between 
directly measured LDL-C and CIMT and a negative association 
between directly measured HDL-C and CIMT, the results from 
the MR analysis support a causal association with LDL-C only. 
Despite differences in cohort characteristics (ie, healthier indi-
viduals and much smaller proportion on lipid-lowering medica-
tion in WHII compared with IMPROVE), the different effect of 
genetic score on lipid levels (smaller in the IMPROVE study) 
and the different SNPs used in the 2 genetic scores (Cardio-
chip versus GLGC), the association between LDL-C and CIMT 
was found to be consistent in both studies. Although the genetic 
scores were comparable instruments for HDL-C and TGs, no 
effect on CIMT was found for these 2 genetic scores.
One criterion for causality is assessing the concordance of 
effect estimates from different study designs. In our study, 
using GLGC genetic variants as instruments for LDL-C 
yielded a 0.04 mm difference in CIMT per mmol/L difference 
in LDL-C. To contextualize these findings, a meta-analysis of 
11 statin trials11 found that after treatment with statins (mean 
treatment duration of 25.6 months), there was a significant 
reduction in the mean LDL-C (pretreatment, 168.6±33.3 mg/
dL; posttreatment, 102.33±27.9 mg/dL; P<0.05; n=2132) and 
also a 0.04 mm (95% CI, 0.028–0.052) difference in mean 
CIMT between statin therapy arm and placebo arm (Bedi et al 
2010).10 This is roughly equivalent to a 0.02 mm decrease in 
CIMT per mmol/L decrease in LDL-C, and therefore reason-
ably consistent with the genetic data.
Clinical Perspective
Randomized controlled drug trials with hard clinical end 
points require a large number of participants and follow-up 
Table 2. Strength of Genetic Instruments
R2 F-Statistic Sample Size
WHII IMPROVE WHII IMPROVE WHII IMPROVE
Cardiochip genetic  
scores
 LDL 0.13 0.03 697 90 4635 3354
 HDL 0.07 0.05 371 181 4745 3410
 TG 0.05 0.04 259 137 4760 3414
GLGC genetic scores
 LDL 0.11 0.02 366 75 3005 3352
 HDL 0.04 0.05 143 194 3052 3342
 TG 0.02 0.02 76 78 3062 3410
R2 and F-statistic obtained from the first stage regression between lipid levels 
and the respective genetic scores.
GLGC indicates Global Lipids Genetic Consortium; HDL, high-density 
lipoprotein; IMPROVE, IMT Progression as Predictors of Vascular Events in a High 
Risk European Population Study22; LDL, low-density lipoprotein; TG, triglyceride; 
and WHII, Whitehall II study.
Table 3. Associations of the Major Lipid Fractions With Carotid IMT in the Whitehall II and IMPROVE Studies
Unadjusted
Adjusted for Sex, Age, Smoking, Diabetes 
Mellitus Status, and Statin Use
Lipid Phenotype Study β (Confidence Interval) P β (95% Confidence Interval) P
LDL-C WHII 0.02 (0.02 to 0.03) 1×10−15 0.01 (0.006 to 0.02) 1×10−05
IMPROVE 0.002 (−0.009 to 0.01) 0.7 0.02 (0.005 to 0.03) 0.006
HDL-C WHII −0.03 (−0.04 to −0.01) 0.0001 −0.02 (−0.04 to −0.01) 0.001
IMPROVE −0.08 (−0.1 to −0.05) 4×10−07 −0.05 (−0.08 to −0.02) 0.004
Triglycerides WHII 0.009 (0.004 to 0.01) 0.001 0.005 (−0.001 to 0.01) 0.08
IMPROVE −0.004 (−0.01 to 0.005) 0.50 −0.005 (−0.01 to 0.004) 0.3
Effect sizes are shown as mm change in CIMT per mmol/L change in lipid level. For IMPROVE, association is shown for the unadjusted analysis and adjusted for sex, 
age, smoking, diabetes status, and statin use.
CIMT indicates carotid intima–media thickness; HDL-C, high-density lipoprotein cholesterol; IMPROVE, IMT Progression as Predictors of Vascular Events in a High Risk 
European Population Study22; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; and WHII, Whitehall II study.
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over a long period, making them technically and financially 
challenging. As a result, clinically related, laboratory-derived 
surrogate end points have been used as alternative end points in 
these situations. CIMT has been used as a surrogate end point 
in many lipid-modifying drug trials to help inform later car-
diovascular disease end-point trials.33–36 However, the suitabil-
ity of CIMT as a surrogate marker in cardiovascular drug trials 
has come under debate because of conflicting trial results, for 
example, the Stop Atherosclerosis in Native Diabetics Study 
(SANDS)37 and Fenofibrate Intervention and Event Lowering 
in Diabetes (FIELD)38 trials. The underlying assumption in 
randomized trials using CIMT as a surrogate marker is that the 
rate of change in CIMT over time in response to drug thera-
pies reflects the change in the risk of cardiovascular outcomes. 
The majority of CIMT trials have short follow-up periods and 
modest sample sizes and, therefore, lack power to identify 
associations with cardiovascular outcomes. Rather, they are 
designed to provide inferences on cardiovascular outcomes 
based on a presumed inverse relationship between atheroscle-
rosis progression and cardiovascular benefit.39
A recent large-scale meta-analysis of 41 randomized trials 
assessing CIMT at baseline and follow-up after treatment,40 
including 18 307 participants, concluded that regression 
of CIMT induced by cardiovascular drug therapies was not 
Figure 2. Instrumental variable analysis. Association of lipid fractions with carotid intima–media thickness obtained from the instrumental 
variable analysis in which lipid genetic scores act as instruments for the nonconfounded effect of each lipid fraction. Effect sizes and 95% 
confidence intervals in each study and summary estimates from a fixed-effect model are shown as millimeter change in carotid intima–
media thickness per mmol/L change in lipid level. FE indicates fixed-effect; GLGC, Global Lipids Genetic Consortium; HDL, high-density 
lipoprotein; IMPROVE, IMT Progression as Predictors of Vascular Events in a High Risk European Population Study22; LDL, low-density 
lipoprotein; and WHII, Whitehall II study.
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associated with a reduction in cardiovascular events. Although 
the meta-analysis was technically sound, the heterogeneity 
in the interventions evaluated, the methods used for CIMT 
measurement, the outcome definition, study design, popula-
tion characteristics, and follow-up time among the 41 trials 
may have reduced the ability to detect an association between 
CIMT and cardiovascular event reductions in such trials.
The aim of the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD)5 Lipid trial was to test whether treat-
ment of patients with type 2 diabetes mellitus with fenofi-
brate, to increase plasma HDL-C levels and reduce plasma 
TG concentrations, would result in additional cardiovascular 
benefit compared with simvastatin (LDL-lowering) therapy 
alone. Although the addition of fenofibrates to statin treatment 
did not show any significant reduction in clinical events in the 
placebo versus treatment groups, subgroup analyses suggested 
benefits of fenofibrate therapy in mixed dyslipidemia individ-
uals. Similar results were reported in post hoc analyses per-
formed in other fibrate studies.41 Therefore, an MR analysis to 
determine causality among HDL-C, TGs, and CIMT in a suffi-
ciently large mixed dyslipidemia sample would be worthwhile.
Our findings suggest that CIMT is likely to be a reliable 
surrogate outcome measure in randomized trials of LDL-
lowering therapy, but because of the lack of evidence for an 
Figure 3. Instrumental variable analysis using lipid levels corrected for statin use. Association of lipid fractions with carotid intima–media 
thickness obtained from the instrumental variable analysis in which lipid genetic scores act as instruments for the nonconfounded effect 
of each lipid fraction. Effect sizes and 95% confidence intervals in each study and summary estimates from a fixed-effect model are 
shown as millimeter change in carotid intima–media thickness per mmol/L change in lipid level. FE indicates fixed-effect; GLGC, Global 
Lipids Genetic Consortium; HDL, high-density lipoprotein; IMPROVE, IMT Progression as Predictors of Vascular Events in a High Risk 
European Population Study22; LDL, low-density lipoprotein; and WHII, Whitehall II study.21
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association of HDL-C and TGs genetic scores, and CIMT, 
they cast doubt on the use of CIMT in trials of HDL-C– and 
TG-modifying therapies.
Previous MR Studies Based on Lipid-associated 
SNPs
To date, there have been few MR studies addressing asso-
ciation of lipids with CIMT or CHD. A study by Aulchenko 
et al42 generated genetic scores for total cholesterol, LDL-C, 
HDL-C, and TGs based on 28 SNPs (identified before the 
GLGC study). They looked at the direct association of the 
genetic scores with CIMT and found only the total choles-
terol genetic score to be associated with CIMT. However, 
they did not use an instrumental variable approach to estimate 
the causal effect. The GLGC19 found 4 lipid-associated SNPs 
to also be associated with CAD, but they did not attempt 
to quantify the causal effect of the lipid fractions using an 
instrumental variable approach. The Triglyceride Coronary 
Disease Genetics Consortium and emerging Risk Factor Col-
laboration compared the risk of genetically (using the APOA5 
SNP rs662799) elevated TGs levels among more than 20 000 
CHD cases and 35 000 controls.30 They concluded that there 
was a causal role for TG-mediated pathway(s) in CHD. How-
ever, the APOA5 variant was also associated with HDL-C 
levels in their study. The association of genetically deter-
mined TG levels with CHD was also attenuated to the null 
after adjusting not only for HDL, but also for non-HDL-C 
and other variables. This nonspecific effect of rs662799 com-
promises 1 key assumption for a valid MR analysis of a bio-
marker and complicates the interpretation of the results. The 
latter 2 studies did not look at the association of lipid-asso-
ciated SNPs with CIMT, which is the objective of this study.
Limitations
The validity of the MR analysis may be compromised by (1) 
population stratification, where allele frequencies and disease 
rates differ between population subgroups; (2) pleiotropy, 
where genetic instruments affect the outcome through >1 
intermediate risk factor, though this is not an issue for cis-
acting SNPs used as instruments for a protein biomarker; (3) 
linkage disequilibrium, where another polymorphism in close 
proximity (and in linkage disequilibrium) to the variant of 
interest, is causing disease through another pathway; and (4) 
weak instrument bias. Analysis in the WHII was restricted to 
whites, and principal component analysis revealed no substan-
tial population stratification. In the IMPROVE study, although 
all individuals were whites, there was population stratification 
that reflected the geographical location from which the sam-
ples were obtained.22 However, the SNPs used to generate the 
GLGC genetic scores were also discovered in individuals of 
European descent from the United States, Europe, or Austra-
lia. Therefore, the scores should be applicable to the general 
European population, and stratification is less likely to be an 
issue in this MR analysis.
In WHII, lipid measures used in the IV analysis were those 
from an earlier phase to CIMT measurements because the 
proportion of statin users at this earlier phase was very low. 
Analysis using lipid measures from the same phase as the 
CIMT measures gave similar results (provided on request). 
Although the 2 studies differ in design, the consistency of 
genetic associations with lipid traits across studies of differing 
design has been a feature of numerous genome-wide associa-
tion studies. Therefore, we present the effect estimates both 
separately and combined.
Often genes act on multiple pathways and may, therefore, 
be associated with multiple intermediate phenotypes, espe-
cially those that act as transcription factors for other genes. 
Some SNPs included in the score may be independently asso-
ciated with other cardiovascular risk factors, and, therefore, 
individually they would not be valid instruments. By combin-
ing these multiple SNPs into 1 score, the problem of pleiot-
ropy can be reduced. An association with 1 polymorphism 
could have arisen by chance or confounding, but associations 
with >1 polymorphism in different genes marking the same 
exposure are unlikely unless the exposure is causal.43 Given 
the large number of lipid genetic variants that have been iden-
tified by different studies, it is possible to generate many inde-
pendent combinations of such variants and from these many 
independent instrumental variable estimates of the causal 
effect of exposure of interest on outcome. It is important to 
note that instrument strength of the Cardiochip genetic scores 
in WHII are likely to be inflated because of discovery bias. 
However, both the Cardiochip and GLGC genetic scores, 
which used only partially overlapping SNP sets, supported the 
causal association of LDL-C with CIMT in each study. Using 
2 different scores containing only partially overlapping SNPs 
gives us confidence that the results are not biased by the SNP 
set used, as the 2 instruments are unlikely to be influenced 
by the same pleiotropy or linkage disequilibrium-induced 
confounding, and their consistency provides strong evidence 
against the notion that reintroduced confounding is generating 
the effect.44
Both Cardiochip and GLGC LDL genetic scores were stron-
ger instruments than the HDL and TG genetic scores in WHII, 
and it remains to be seen whether the addition of more SNPs 
that increase the HDL and TG instrument strength will alter 
the conclusions based on this analysis. However, it is impor-
tant to note that all genetic scores had comparable instrument 
strength in the IMPROVE study, and despite the HDL genetic 
scores being the strongest instruments in this cohort, causality 
was only observed for LDL-C.
Our method for generating genetic scores makes several 
assumptions: additive effects of alleles, no gene–gene inter-
actions, and a linear effect of lipids on CIMT. Although not 
explored in this work, if these assumptions did not hold, it 
would be possible to incorporate such knowledge into the 
model. An alternative to using a composite genetic score as 
an instrument is to use the SNPs as multiple instruments. 
Although this may improve the power, the large number of 
SNPs may potentially create a weak instrumental variable 
problem.45 A comparison of the different methodologies 
would be worthwhile but is beyond the scope of this report.
Conclusion
An MR analysis, using the instrumental variable regression 
approach, supports a causal association between LDL-C and 
CIMT, indicating CIMT to be a useful surrogate end point in 
clinical trials of LDL-lowering medications. Whether HDL-C 
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or TGs are causally associated with CIMT is uncertain. Thus, 
we conclude that, at present, the suitability of CIMT as a sur-
rogate marker in trials of therapies targeting these lipid frac-
tions is questionable and requires further study.
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CLINICAL PERSPECTIVE
Carotid intima–media thickness (CIMT) (assessed by ultrasound) is a noninvasive measure of atherosclerosis associated 
with a higher risk of stroke and coronary heart disease events in prospective observational studies. CIMT is also widely used 
as a surrogate outcome measure in clinical trials. Statins reduce progression or induce regression of CIMT in proportion to 
the degree of low-density lipoprotein cholesterol lowering, an effect consistent with the reduction in risk of coronary heart 
disease events. However, the extent of any causal association between high-density lipoprotein cholesterol or triglycerides 
and CIMT and coronary heart disease events is less clear. This mendelian randomization analysis using common variants 
in genes primarily associated with low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or triglycerides 
provided evidence for a causal association between low-density lipoprotein cholesterol and CIMT, but not between high-
density lipoprotein cholesterol or triglycerides and CIMT. The findings support the use of CIMT as a surrogate outcome 
measure in trials of low-density lipoprotein cholesterol-lowering drugs. CIMT may be a less useful surrogate end point in 
clinical trials of primarily high-density lipoprotein cholesterol– or triglyceride-modifying therapies.
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Methods 
Lipid and carotid intima-media thickness measurements 
In WHII, serum for lipid analyses was refrigerated at -4C and assayed within 72 hours. 
Cholesterol and triglycerides were measured with the use of a Cobas Fara centrifugal 
analyzer (Roche Diagnostics System, Nutley, NJ). HDL-cholesterol was measured by 
precipitating non-HDL cholesterol with dextran sulfate-magnesium chloride with the use of a 
centrifuge and measuring cholesterol in the supernatant fluid (1). LDL-C concentration was 
calculated using the Friedewald formula (2). Phase 3 provided the first comprehensive 
dataset for lipid measurements and was considered the baseline phase. Ultrasound vascular 
measurements were taken at Phase 7 (2003–2004). Participants were examined in a supine 
position, with the head turned to a 45 degree angle away from the side to be scanned. CIMT 
was measured in the right and left common carotid arteries. Longitudinal images of the 
common carotid artery, triggered on the R-wave of the ECG, were magnified and recorded in 
DICOM format as a cine loop, on the hard drive of the ultrasound machine for later analysis. 
The common CIMT was measured at its thickest part 1 cm proximal to the bifurcation. A 
measurement was taken between the leading edge of the intima and the media adventitia on 
3 separate images on each side using electronic callipers and the mean of the 6 measures 
2 
 
was used for analysis. The overall coefficient of variation for repeated measures of CIMT 
was 4.7% (N = 89) (1).  
In IMPROVE, blood sampling for laboratory tests was performed after an overnight fast. 
Serum was frozen at –80oC prior to shipment for centralized biochemical analyses and 
biobanking in Stockholm (Karolinska Institute  Stockholm, Sweden). Serum concentrations of 
total, HDL cholesterol and triglycerides were analyzed in a centralized laboratory with the 
use of LX Beckman instruments. Cholesterol and triglycerides were measured with 
enzymatic methods. LDL-C concentration was calculated using the Friedewald (2). The 
CIMT variable selected for this analysis was the maximum IMT of the CC which was 
measured as follows: The far walls of the left and right common carotid (CC) artery were 
visualized in anterior, lateral, and posterior projections and recorded on sVHS videotapes. 
Measurements were taken at the thickest part of common carotids 1 cm proximal to the 
bifurcation. The far walls of the CCs in their entire length were measured in at least three 
different images on each side using dedicated software able to automatically recognize the 
leading edge of the intima and the media adventitia. For each segment the mean of the 6 
measures was used in this analysis. The overall coefficient of variation for repeated 
measures of CIMT was 3.9% (N = 121) (3). 
 
 
Genotyping and quality control 
For WHII participants, DNA was extracted from blood samples (via magnetic bead 
technology; Medical Solutions, Nottingham, UK) and normalized to a concentration of 50 
ng/μl. 5592 samples were genotyped using the Illumina Human Cardiochip(4) and 3413 of 
these were also genotyped using the Illumina CardioMetabochip (also referred to as the 
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Illumina Metabochip) (5). Genotyping of the two APOE snps (rs7412 and rs429358) was 
previously carried out using a universal heteroduplex generator (6). 
In the IMPROVE study, several biological samples were kept in a biobank. Specifically, the 
biobank contains 14 aliquots of 0.5 mL EDTA plasma and 8 aliquots of 0.5 mL serum for 
each subject. In addition, for each subject, 2 × 5 mL whole blood was stored for DNA 
extraction. DNA was purified (in the Atherosclerosis Research Unit, Karolinska Institute 
Stockholm, Sweden) from all patients who signed informed consent for genetic studies. In 
total 3695 samples were genotyped using the Illumina CardioMetabochip.  
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Beta SE P-value 
rs10402271 BCAM/PVRL2 Y N G 0.325 0.15 0.022 1.80E-11 0.350 0.022 0.025 3.90E-01 
rs11220462 ST3GAL4 N Y A 0.131 0.083 0.038 3.10E-02 0.158 -0.042 0.033 2.00E-01 
rs11591147 PCSK9 Y N G 0.984 0.549 0.082 2.50E-11 0.983 0.501 0.095 1.40E-07 
rs12721109 APOC4 Y N G 0.978 0.554 0.073 3.00E-14 NA NA NA NA 
rs12740374 CELSR2 Y N G 0.791 0.154 0.026 2.80E-09 0.807 0.061 0.032 5.20E-02 
rs12916 HMGCR Y N C 0.405 0.124 0.021 6.00E-09 0.436 0.07 0.025 5.10E-03 
rs1367117 APOB N Y A 0.335 0.139 0.027 2.70E-07 0.310 0.025 0.027 3.50E-01 
rs1564348 SLC22A1 N Y T 0.826 -0.007 0.034 8.30E-01 0.849 -0.041 0.034 2.30E-01 
rs17231506 CETP Y N C 0.676 0.109 0.022 1.00E-06 0.716 0.025 0.027 3.60E-01 
rs17248720 LDLR Y N C 0.872 0.312 0.031 6.80E-24 0.895 0.183 0.04 4.40E-06 
rs1800562 HFE N Y G 0.928 -0.013 0.049 7.90E-01 0.964 0.097 0.065 1.40E-01 
rs2072560 APOA5 Y N T 0.061 0.21 0.044 1.70E-06 0.089 0.093 0.043 3.10E-02 
rs2228671 LDLR Y N C 0.867 0.188 0.03 7.90E-10 0.896 0.169 0.04 2.50E-05 
rs2479409 PCSK9 N Y G 0.346 0.058 0.027 3.20E-02 0.341 0.044 0.025 8.30E-02 
rs283813 PVRL2 Y N T 0.930 0.18 0.041 1.40E-05 0.926 0.059 0.047 2.10E-01 
rs3757354 MYLIP N Y C 0.792 0.014 0.032 6.50E-01 0.784 0.073 0.029 1.40E-02 
rs4299376 ABCG8 Y Y G 0.324 0.152 0.027 2.50E-08 NA NA NA NA 
rs562338 APOB Y N G 0.822 0.173 0.027 3.20E-10 NA NA NA NA 
rs629301 CELSR2 Y Y T 0.790 0.163 0.031 2.00E-07 NA NA NA NA 
rs6511720 LDLR N Y G 0.869 0.302 0.038 1.20E-15 0.896 0.188 0.04 2.70E-06 
rs8017377 KIAA1305 N Y A 0.479 0.037 0.025 1.50E-01 0.444 0.001 0.024 9.80E-01 
rs8110695 LDLR Y N T 0.779 0.14 0.025 3.70E-08 0.795 0.103 0.03 6.50E-04 




         Total 16 11     NA – SNP not present in dataset 
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Univariate Association in WHII Univariate Association in IMPROVE 
Risk Allele Freq beta se pval Risk Allele Freq beta se pval 
rs11820589 BUD13 yes no A 0.064 -0.068 0.017 7.1E-05 0.076 -0.055 0.016 6.5E-04 
rs11869286 STARD3 no yes G 0.343 -0.005 0.011 6.0E-01 0.323 0.000 0.009 9.9E-01 
rs12708967 CETP yes no C 0.193 -0.090 0.010 6.2E-18 0.177 -0.056 0.011 4.9E-07 
rs12967135 MC4R no yes A 0.236 0.006 0.012 6.3E-01 NA NA NA NA 
rs13107325 SLC39A8 no yes T 0.072 -0.025 0.020 2.1E-01 0.054 -0.048 0.019 1.1E-02 
rs1532085 LIPC no yes G 0.617 -0.044 0.010 2.5E-05 0.602 -0.034 0.009 1.3E-04 
rs1689800 ZNF648 no yes G 0.356 -0.031 0.010 3.2E-03 0.346 -0.013 0.009 1.4E-01 
rs16942887 PSKH1 no yes G 0.885 -0.032 0.016 4.0E-02 0.863 -0.044 0.013 4.8E-04 
rs17231506 CETP yes no C 0.676 -0.100 0.009 1.2E-29 0.716 -0.089 0.010 1.7E-20 
rs17410962 LPL yes no G 0.874 -0.061 0.013 1.5E-06 0.874 -0.051 0.013 1.1E-04 
rs1800961 HNF4A no yes T 0.030 -0.085 0.030 4.6E-03 0.032 -0.030 0.024 2.1E-01 
rs181362 UBE2L3 no yes T 0.197 -0.006 0.013 6.2E-01 0.248 -0.009 0.010 3.5E-01 
rs1883025 ABCA1 no yes T 0.254 -0.027 0.011 1.8E-02 0.232 -0.046 0.010 5.5E-06 
rs2072560 APOA5 yes no T 0.061 -0.068 0.017 9.4E-05 0.089 -0.033 0.015 2.8E-02 
rs2293889 TRPS1 no yes T 0.431 -0.031 0.010 2.8E-03 0.364 -0.013 0.009 1.4E-01 
rs261342 LIPC yes no C 0.780 -0.053 0.010 2.4E-07 NA NA NA NA 
rs2652834 LACTB no yes A 0.186 -0.020 0.013 1.2E-01 0.220 -0.005 0.010 6.2E-01 
rs2814944 C6orf106 no yes A 0.144 0.008 0.015 5.6E-01 0.169 0.002 0.012 8.6E-01 
rs2923084 AMPD3 no yes G 0.185 -0.004 0.013 7.4E-01 0.178 -0.004 0.011 7.5E-01 
rs2925979 CMIP no yes T 0.295 -0.015 0.011 1.9E-01 0.318 -0.019 0.009 4.8E-02 
rs301 LPL yes no T 0.754 -0.052 0.010 7.6E-08 0.779 -0.057 0.011 6.8E-08 
rs3136441 F2 no yes T 0.866 -0.011 0.015 4.8E-01 0.842 -0.032 0.012 8.1E-03 
rs3764261 CETP no yes C 0.675 -0.100 0.011 1.8E-20 0.713 -0.089 0.010 2.1E-20 
rs386000 LILRA3 no yes G NA NA NA NA 0.794 -0.025 0.010 1.8E-02 
rs4129767 PGS1 no yes G 0.515 0.011 0.010 2.8E-01 0.474 -0.016 0.009 6.6E-02 
rs4148008 ABCA8 no yes G 0.322 -0.002 0.011 8.8E-01 0.336 -0.008 0.009 3.7E-01 
rs4660293 PABPC4 no yes G 0.244 -0.018 0.012 1.3E-01 0.237 -0.017 0.010 9.7E-02 
rs4731702 KLF14 no yes C 0.496 0.008 0.010 4.2E-01 0.561 -0.015 0.009 8.2E-02 
rs4775041 LIPC yes no G 0.706 -0.042 0.009 5.7E-06 0.692 -0.039 0.009 2.7E-05 
rs4846914 GALNT2 no yes G 0.399 -0.016 0.010 1.2E-01 0.426 -0.024 0.009 6.2E-03 
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rs581080 C9orf52 no yes G 0.180 -0.012 0.013 3.8E-01 0.183 -0.007 0.011 5.5E-01 
rs5880 CETP yes no C 0.052 -0.102 0.019 3.6E-08 0.041 -0.086 0.022 7.7E-05 
rs5883 CETP yes no C 0.945 -0.084 0.018 2.9E-06 0.944 -0.058 0.019 2.1E-03 
rs6065906 PLTP no yes C 0.184 -0.025 0.013 5.3E-02 0.177 -0.040 0.011 4.4E-04 
rs6450176 ARL15 no yes A 0.254 0.005 0.012 6.6E-01 0.271 -0.032 0.010 1.2E-03 
rs711752 CETP yes no G 0.569 -0.089 0.008 3.2E-26 0.582 -0.070 0.009 8.8E-16 
rs7134375 PDE3A no yes C 0.568 -0.010 0.010 3.3E-01 0.579 -0.003 0.009 7.6E-01 
rs737337 DOCK6 no yes C 0.078 0.011 0.018 5.5E-01 0.077 -0.037 0.016 2.3E-02 
rs838880 SCARB1 no yes T 0.693 -0.037 0.011 5.6E-04 0.653 -0.021 0.009 2.1E-02 
rs9987289 PPP1R3B no yes A 0.090 -0.049 0.017 4.8E-03 0.108 -0.031 0.014 2.6E-02 
rs9989419 CETP yes no A 0.396 -0.073 0.008 1.3E-17 0.397 -0.041 0.009 3.7E-06 












Score Risk Allele 
Univariate Association in WHII Univariate Association in IMPROVE  
Risk Allele Freq beta se pval 
Risk Allele 
Freq beta se pval 
rs10195252 COBLL1 no yes T 0.586 0.032 0.030 2.9E-01 0.625 0.095 0.031 1.9E-03 
rs10503669 LPL yes no C 0.894 0.181 0.037 1.2E-06 0.905 0.216 0.052 2.9E-05 
rs10750097 APOA5 yes no G 0.209 0.156 0.028 1.8E-08 NA NA NA NA 
rs11613352 R3HDM2 no yes C 0.760 0.031 0.034 3.7E-01 0.789 0.074 0.036 3.7E-02 
rs11776767 PINX1 no yes C 0.377 0.020 0.030 5.0E-01 0.352 0.020 0.031 5.2E-01 
rs12286037 ZNF259 yes no T 0.064 0.221 0.046 1.5E-06 0.077 0.394 0.056 1.7E-12 
rs1260326 GCKR yes yes T 0.399 0.156 0.030 1.7E-07 0.447 0.115 0.029 8.0E-05 
rs12678919 LPL no yes A 0.898 0.146 0.048 2.6E-03 0.905 0.213 0.052 3.8E-05 
rs17108993 GPR120 yes no G 0.033 0.273 0.063 1.4E-05 NA NA NA NA 
rs17145713 BAZ1B yes no C 0.803 0.129 0.029 6.5E-06 0.833 0.085 0.040 3.4E-02 
rs17145738 TBL2 no yes C 0.883 0.140 0.046 2.2E-03 0.894 0.112 0.049 2.3E-02 
rs17321515 TRIB1 yes no A 0.528 0.079 0.023 4.5E-04 NA NA NA NA 
rs174546 FADS1 no yes T 0.348 0.064 0.030 3.3E-02 0.340 0.062 0.031 4.9E-02 
rs2068888 CyP26A1 no yes G 0.562 0.014 0.029 6.3E-01 0.545 0.043 0.030 1.4E-01 
rs2131925 DOCK7 no yes T 0.653 0.115 0.030 1.6E-04 0.730 0.063 0.034 6.1E-02 
rs2304128 GMIP yes no G 0.914 0.180 0.040 8.5E-06 0.927 0.046 0.057 4.1E-01 
rs2412710 GANC/CAPN3 no yes A 0.016 0.104 0.115 3.6E-01 0.025 0.309 0.096 1.3E-03 
rs285 LPL yes no C 0.530 0.110 0.023 1.7E-06 0.517 0.092 0.030 2.1E-03 
rs2954029 TRIB1 no yes A 0.541 0.069 0.029 1.6E-02 0.577 0.121 0.029 3.7E-05 
rs3289 LPL yes no C 0.027 0.250 0.070 3.5E-04 0.032 0.241 0.086 4.9E-03 
rs331 LPL yes no G 0.726 0.128 0.025 4.0E-07 0.750 0.154 0.035 1.2E-05 
rs33989105 APOC3 yes no T 0.250 0.108 0.026 4.5E-05 NA NA NA NA 
rs442177 AFF1 no yes T 0.591 0.031 0.030 3.1E-01 0.573 0.035 0.030 2.4E-01 
rs5756931 PLA2G6 no yes T 0.606 0.036 0.030 2.3E-01 0.612 0.034 0.030 2.7E-01 
rs645040 MSL2L1 no yes T 0.772 0.066 0.034 5.4E-02 0.805 -0.039 0.037 3.0E-01 
rs651821 APOA5 yes no C 0.062 0.407 0.046 2.3E-18 0.093 0.332 0.051 9.9E-11 
rs9686661 MAP3K1 no yes T 0.197 0.032 0.036 3.7E-01 0.196 0.092 0.038 1.6E-02 
Total    13 15                   
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Supplementary figure 1: Strength and specificity of GLGC gene scores in WHII 
The figure compares the strength and specificity of single SNPs versus gene scores as 
instruments for lipid fractions. The proportion of variance in observed LDL-C, HDL-C and 
triglyceride levels that is explained by each genetic instrument (R2 derived from the 
regression of observed lipid levels with the genetic instrument) is shown as a measure of the 
strength of the instrument for that lipid fraction. Specificity of each instrument is alluded by 
the comparison of R2 for a lipid-fraction-specific instrument with other lipid fractions e.g. R2 
derived from the regression of LDL score with LDL-C levels compared to R2 derived from the 
regression of LDL score with HDL-C or triglyceride levels. 
 
 
 
 
 
